Search

Displaying results 951 - 960 of 1186 in total
  1. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. … [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.

    Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors, Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors
  2. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic effi...

  3. Drug

    Celivarone

    go.drugbank.com/drugs/DB16012
    Investigational

    Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent

  4. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    This transformation mimics the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of open tissues.

  5. Target

    Low affinity immunoglobulin gamma Fc region receptor III-B

    go.drugbank.com/bio_entities/BE0000901
    TargetHumans

    Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1
  6. Target

    Low affinity immunoglobulin gamma Fc region receptor II-b

    go.drugbank.com/bio_entities/BE0002099
    TargetHumans

    Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. … Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-bSynonyms: IgG Fc receptor II-b
  7. Target

    Transient receptor potential cation channel subfamily V member 6

    go.drugbank.com/bio_entities/BE0005102
    TransporterTargetHumans

    Calcium selective cation channel that mediates Ca(2+) uptake in various tissues, including the intestine (PubMed:11097838, PubMed:11248124, PubMed:11278579, PubMed:15184369, PubMed:23612980, PubMed:29258289). Important for normal Ca(2+) ...

    Polypeptides: Transient receptor potential cation channel subfamily V member 6
  8. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    [A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart … and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma

    Categories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity
  9. Drug

    Elgemtumab

    go.drugbank.com/drugs/DB15430
    Investigational

    Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

  10. Drug

    LX-7101

    go.drugbank.com/drugs/DB16009
    Investigational

    LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).